Table 4 |
|||
|
Accumulated incidents of adverse symptoms reported by the subjects during the intervention period |
|||
|
Symptoms |
Placebo group (n = 40) |
b240 group1 (n = 40) |
P value |
|
|
|||
|
Common cold |
4 (10.0%) |
2 (5.0%) |
0.396 |
|
Headache |
1 (2.5%) |
2 (5.0%) |
0.556 |
|
Anorexia |
2 (5.0%) |
0 (0.0%) |
0.152 |
|
Nasal discharge |
4 (10.0%) |
7 (17.5%) |
0.330 |
|
Abdominal distension |
0 (0.0%) |
1 (2.5%) |
0.314 |
|
Abdominal pain |
0 (0.0%) |
1 (2.5%) |
0.314 |
|
|
|||
|
Data are represented by number of symptoms (incidence of symptoms) during the intervention period. P value, by the chi-square test. 14 × 109 cells of heat-killed L. pentosus strain b240 per day for 12 weeks. |
|||
|
Kotani et al. Immunity & Ageing 2010 7:11 doi:10.1186/1742-4933-7-11 |
|||
